[PDF][PDF] Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma

K Yamashita, S Upadhyay, M Osada, MO Hoque… - Cancer cell, 2002 - cell.com
K Yamashita, S Upadhyay, M Osada, MO Hoque, Y Xiao, M Mori, F Sato, SJ Meltzer
Cancer cell, 2002cell.com
We performed a comprehensive survey of commonly inactivated tumor suppressor genes in
esophageal squamous cell carcinoma (ESCC) based on functional reactivation of
epigenetically silenced tumor suppressor genes by 5-aza-2′-deoxycytidine and trichostatin
A using microarrays containing 12599 genes. Among 58 genes identified by this approach,
44 (76%) harbored dense CpG islands in the promoter regions. Thirteen of twenty-two tested
gene promoters were methylated in cell lines, and ten in primary ESCC accompanied by …
Abstract
We performed a comprehensive survey of commonly inactivated tumor suppressor genes in esophageal squamous cell carcinoma (ESCC) based on functional reactivation of epigenetically silenced tumor suppressor genes by 5-aza-2′-deoxycytidine and trichostatin A using microarrays containing 12599 genes. Among 58 genes identified by this approach, 44 (76%) harbored dense CpG islands in the promoter regions. Thirteen of twenty-two tested gene promoters were methylated in cell lines, and ten in primary ESCC accompanied by silencing at the mRNA level. Potent growth suppressive activity of three genes including CRIP-1, Apolipoprotein D, and Neuromedin U in ESCC cells was demonstrated by colony focus assays. Pharmacologic reversal of epigenetic silencing is a powerful approach for comprehensive identification of tumor suppressor genes in human cancers.
cell.com